(redirected from AL amyloidosis)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to AL amyloidosis: AA amyloidosis, Cardiac amyloidosis


Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.


(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism


n. amiloidosis, acumulación de amiloide en los tejidos.


n amiloidosis f
References in periodicals archive ?
Ixazomib is a breakthrough drug showing activity and organ improvement in most of these heavily pretreated AL amyloidosis patients, said Professor Giampaolo Merlini, Director, Center for Research and Treatment of Systemic Amyloidosis, University of Pavia, Italy.
Odiick's commitment to bettering other peoples' lives was recognized by fans, who gathered outside Vancouver General Hospital to show their respect when Odjick made it known through the Canucks website that he had been diagnosed with AL amyloidosis, a rare terminal disease.
Primary AL amyloidosis has clonal B-cell dyscrasia, including multiple myelomas, B-cell lymphoma, Waldenstrom macroglobulinemia, or another plasma cell neoplasia.
For example, AL amyloidosis, a common systemic form, is due to overproduction of immunoglobulin components associated with immunocyte dyscrasias, and effective treatment may require chemotherapy.
Approximately 4,500 people in the UK are diagnosed with Myeloma while 500 to 600 people in the UK are diagnosed with AL amyloidosis but treatment for both conditions is the same.
Two global phase 3 trials, TOURMALINE-MM1, to investigate MLN9708 in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma and TOURMALINE-AL1, to investigate MLN9708 plus dexamethasone in patients with relapsed or refractory light chain AL amyloidosis were initiated in 2012.
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Donald was diagnosed with the disease AL amyloidosis, where an abnormal protein builds up in organs, such as the kidneys and spleen, causing damage.
The results revealed a lot of protein in his urine and the findings were sent to the renal unit at Newcastle's Freeman Hospital, where he underwent a kidney biopsy and was later diagnosed with AL amyloidosis this year.
Although high dose melphalan with ASCT is an effective therapy for systemic AL amyloidosis, it is associated with high mortality.
We foresee the use of sFLC and Hevylite tests to be important and critical diagnostic tools to clinicians in assessing multiple myeloma and AL amyloidosis and managing patients with B cell dyscrasias.